miRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
pharmaceutical investing miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides
pharmaceutical investing miRagen Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update